Ulrich Jäger – VJRegenMed

Practical aspects of CAR T-cell therapy

Marta Palhas — Fri, 26 Feb 2021 14:08:21 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview of the topics discussed in the session he chaired on practical aspects of CAR T-cell therapy. CAR T-cell immunotherapy has radically altered the treatment of B-cell malignancies. Prof. Jäger outlines that in the setting of diffuse large B-cell lymphoma, the approved CAR-T products are being integrated into daily clinical practice. However, patient selection remains a challenge in the field. The new and exciting field of BCMA CAR T-cells in multiple myeloma was also addressed during the session. This interview took place during the 3rd European CAR T-cell Meeting.

Updates on CAR T-cell therapy in B-cell malignancies

Marta Palhas — Fri, 26 Feb 2021 14:08:20 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the progress and future directions in CAR T-cell therapy for the treatment of B-cell malignancies. The availability of CAR-T has altered the current treatment algorithm for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Indications will likely expand to other disease entities and earlier lines of therapy. Future directions include products targeting multiple tumor antigens to overcome resistance. This interview took place during the 3rd European CAR T-cell Meeting.

Liso-cel for R/R large B-cell lymphoma

Marta Palhas — Fri, 26 Feb 2021 14:08:19 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the recent FDA approval of lisocabtagene maraleucel (liso-cel) for relapsed or refractory (R/R) large B-cell lymphoma. Prof. Jäger considers this approval another milestone in the lymphoma field that now has three CAR-T products available. The approval of liso-cel in Europe is expected soon. This interview took place during the 3rd European CAR T-cell Meeting.